Regenerex Pharma (RGPX) Retained Earnings (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Retained Earnings data on file, last reported at -$9.6 million in Q3 2025.

• Retained Earnings for Q3 2025 came in at -$9.6 million, down 49.9% year-over-year; the trailing twelve-month figure through Sep 2025 was -$9.6 million (down 49.9% YoY), and the FY2025 annual result was -$8.1 million, down 45.0% from the prior year.
• Retained Earnings fell to -$9.6 million in Q3 2025 per RGPX's latest filing, from -$8.8 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$1.7 million in Q1 2021 and troughed at -$9.6 million in Q3 2025.
• A 5-year average of -$4.3 million and a median of -$2.3 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings declined 7.1% in 2023, then tumbled 171.03% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$1.9 million in 2021, then retreated by 7.4% to -$2.0 million in 2022, then plunged by 162.77% to -$5.3 million in 2023, then dropped by 26.48% to -$6.7 million in 2024, then plunged by 42.9% to -$9.6 million in 2025.
• Business Quant data shows RGPX's Retained Earnings at -$9.6 million in Q3 2025, -$8.8 million in Q2 2025, and -$8.1 million in Q1 2025.